Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ15687MR)

This product GTTS-WQ15687MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001025366.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	7422
UniProt ID	P15692

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15687MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15038MR	IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	SRF-231
GTTS-WQ2398MR	IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	AMG 110
GTTS-WQ1644MR	IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	ACT-017
GTTS-WQ3048MR	IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	Anti-PTK7 ADC
GTTS-WQ8197MR	IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	hLIV22
GTTS-WQ10581MR	IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	LY-3127804
GTTS-WQ10430MR	IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	LY-2495655
GTTS-WQ5183MR	IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	CAT-354

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.